List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/369660/publications.pdf Version: 2024-02-01

		71061	60583
208	7,941	41	81
papers	citations	h-index	g-index
235 all docs	235 docs citations	235 times ranked	5970 citing authors

Διρερτίι

#	ARTICLE Permeabilized L Nonresenved Human Henatocytes as an Evogenous Metabolic System in a Novel	IF	CITATIONS
1	Metabolized Cryopreserved Human repaccytes as an Exogenous Metabolic System in a Nover Metabolized Cryopreserved Human repaccytes as an Exogenous Metabolic System in a Nover Detoxification of Drugs Associated with Drug-Induced Liver Injuries: Results with Acetaminophen, Amiodarone, Cyclophosphamide, Ketoconazole, Nefazodone, and Troglitazone. Drug Metabolism and	1.7	2
2	Effects of Overexpression of Fibroblast Growth Factor 15/19 on Hepatic Drug Metabolizing Enzymes. Drug Metabolism and Disposition, 2022, 50, 468-477.	1.7	2
3	Evaluation of Hepatic Uptake of OATP1B Substrates by Short Term-Cultured Plated Human Hepatocytes: Comparison With Isolated Suspended Hepatocytes. Journal of Pharmaceutical Sciences, 2021, 110, 376-387.	1.6	8
4	MetMax Human Hepatocyte/HEK Cytotoxic Reactive Metabolite Assay as a Potential In Vitro Experimental System for the Identification of DILI Drugs. FASEB Journal, 2021, 35, .	0.2	0
5	3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration. Clinical and Translational Science, 2021, 14, 1659-1680.	1.5	77
6	Messenger RNA Expression of Albumin, Transferrin, Transthyretin, Asialoglycoprotein Receptor, Cytochrome P450 Isoform, Uptake Transporter, and Efflux Transporter Genes as a Function of Culture Duration in Prolonged Cultured Cryopreserved Human Hepatocytes as Collagen-Matrigel Sandwich Cultures: Evidence for Redifferentiation upon Prolonged Culturing. Drug Metabolism and	1.7	2
7	Disposition, 2021, 49, 790-802 Prolonged cultured human hepatocytes as an in vitro experimental system for the evaluation of potency and duration of activity of RNA therapeutics: Demonstration of prolonged duration of gene silencing effects of a GalNAc-conjugated human hypoxanthine phosphoribosyl transferase (HPRT1) siPNA Biochemical Pharmacology, 2021, 189, 114374	2.0	6
8	P107 - A comparison of enteric and hepatic metabolism using in vitro enteric and hepatic experimental systems: Cryopreserved human enterocytes, metmax cryopreserved enterocytes, cryopreserved human intestinal mucosa, cryopreserved human hepatocytes, and metmax cryopreserved human hepatocytes. Drug Metabolism and Pharmacokinetics, 2020, 35, S54-S55.	1.1	0
9	P113 - Application of metmax human hepatocytes in the identification of detoxification pathways of protoxicants. Drug Metabolism and Pharmacokinetics, 2020, 35, S56-S57.	1.1	Ο
10	P114 - Recovery of drug metabolizing enzyme and transporter gene expression in prolonged cultures of confluent 2D-human hepatocyte cultures. Drug Metabolism and Pharmacokinetics, 2020, 35, S57.	1.1	0
11	Application of Cryopreserved Human Intestinal Mucosa and Cryopreserved Human Enterocytes in the Evaluation of Herb-Drug Interactions: Evaluation of CYP3A Inhibitory Potential of Grapefruit Juice and Commercial Formulations of Twenty-Nine Herbal Supplements. Drug Metabolism and Disposition, 2020, 48, 1084-1091.	1.7	8
12	P108 - Effects of organic solvents on pravastatin uptake in human hepatocytes. Drug Metabolism and Pharmacokinetics, 2020, 35, S55.	1.1	0
13	Interâ€individual and interâ€regional variations in enteric drug metabolizing enzyme activities: Results with cryopreserved human intestinal mucosal epithelia (CHIM) from the small intestines of 14 donors. Pharmacology Research and Perspectives, 2020, 8, e00645.	1.1	11
14	Regional Proteomic Quantification of Clinically Relevant Non-Cytochrome P450 Enzymes along the Human Small Intestine. Drug Metabolism and Disposition, 2020, 48, 528-536.	1.7	27
15	In vitro evaluation of the metabolic stability of nine fragrance chemicals in trout and human hepatocytes. Journal of Applied Toxicology, 2020, 40, 1421-1434.	1.4	4
16	In Vitro Human Cell–Based Experimental Models for the Evaluation of Enteric Metabolism and Drug Interaction Potential of Drugs and Natural Products. Drug Metabolism and Disposition, 2020, 48, 980-992.	1.7	12
17	Comparison of uptake transporter functions in hepatocytes in different species to determine the optimal model for evaluating drug transporter activities in humans. Xenobiotica, 2019, 49, 852-862.	0.5	17
18	Cryopreserved human intestinal mucosa as a 3-Dimensional organoid culture for the evaluation of inestinal drug metabolism, drug-drug interactions, enterotoxicity, and enteropharmacology. Drug Metabolism and Pharmacokinetics, 2019, 34, S46.	1.1	0

#	Article	IF	CITATIONS
19	Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human) Tj ETQq1 1 0.7843	l 41r.gBT /C	Overlock 10
20	In vitro assay for the estimation of hepatic drug exposure: A comparison of drug uptake and exposure in hepatocytes cultured in protein free medium and 100% human plasma. FASEB Journal, 2019, 33, 507.2.	0.2	0
21	A Novel In Vitro Experimental System for the Evaluation of Drug Metabolism: Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Cryopreserved Human Hepatocytes). Drug Metabolism and Disposition, 2018, 46, 1608-1616.	1.7	11
22	Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 251-258.	1.3	19
23	P450 induction in cryopreserved hepatocytes from PXR and CAR nuclear receptor knock-out rats. Drug Metabolism and Pharmacokinetics, 2018, 33, S87-S88.	1.1	0
24	Evaluation of Drug-Induced Liver Injuries (DILI) with Human Hepatocytes: Scientific Rationale and Experimental Approaches. Methods in Pharmacology and Toxicology, 2018, , 179-197.	0.1	0
25	Metabolism-dependent cytotoxicity of citrinin and ochratoxin A alone and in combination as assessed adopting integrated discrete multiple organ co-culture (IdMOC). Toxicology in Vitro, 2018, 46, 166-177.	1.1	16
26	Alterations in gene expression in vitamin Dâ€deficiency: Downâ€regulation of liver Cyp7a1 and renal Oat3 in mice. Biopharmaceutics and Drug Disposition, 2018, 39, 99-115.	1.1	11
27	Application of MetMaxâ,,¢ pooled donor human hepatocytes in a higher throughput assay for human hepatic metabolic stability screening. Drug Metabolism and Pharmacokinetics, 2018, 33, S61-S62.	1.1	0
28	A comparison of adult and neonatal human hepatocytes in drug metabolizing enzyme activities. Drug Metabolism and Pharmacokinetics, 2018, 33, S80.	1.1	2
29	A Novel In vitro Experimental System for the Evaluation of Enteric Drug Metabolism: Cofactor-Supplemented Permeabilized Cryopreserved Human Enterocytes (MetMaxâ,,¢ Cryopreserved) Tj ETQq1	1 <b>0.7</b> 843	1411gBT/Ove
30	Evaluation of herb-drug interactions with metmaxâ,,¢ pooled donor human enterocytes: Results with twenty eight commonly used herbal supplements. Drug Metabolism and Pharmacokinetics, 2018, 33, S62.	1.1	1
31	Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism. Biochemical Pharmacology, 2018, 156, 32-42.	2.0	35
32	Strategies and limitations associated with in vitro characterization of vitamin D receptor activators. Biochemical Pharmacology, 2018, 155, 547-561.	2.0	1
33	Cryopreserved Human Intestinal Mucosal Epithelium: A Novel In Vitro Experimental System for the Evaluation of Enteric Drug Metabolism, Cytochrome P450 Induction, and Enterotoxicity. Drug Metabolism and Disposition, 2018, 46, 1562-1571.	1.7	31
34	Utility of Pooled Cryopreserved Human Enterocytes as an In vitro Model for Assessing Intestinal Clearance and Drug-Drug Interactions. Drug Metabolism Letters, 2018, 12, 3-13.	0.5	16
35	Human Enterocytes as an In Vitro Model for the Evaluation of Intestinal Drug Metabolism: Characterization of Drug-Metabolizing Enzyme Activities of Cryopreserved Human Enterocytes from Twenty-Four Donors. Drug Metabolism and Disposition, 2017, 45, 686-691.	1.7	49
36	Disrupted Murine Gut–to–Human Liver Signaling Alters Bile Acid Homeostasis in Humanized Mouse Liver Models. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 174-191.	1.3	23

#	Article	IF	CITATIONS
37	Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations. Environmental and Molecular Mutagenesis, 2017, 58, 264-283.	0.9	57
38	Generalized Additive Mixed-Models for Pharmacology Using Integrated Discrete Multiple Organ Co-Culture. PLoS ONE, 2016, 11, e0152985.	1.1	3
39	Functional Integrity of the Chimeric (Humanized) Mouse Liver: Enzyme Zonation, Physiologic Spaces, and Hepatic Enzymes and Transporters. Drug Metabolism and Disposition, 2016, 44, 1524-1535.	1.7	12
40	Endoplasmic Reticulum Stress Induction and ERK1/2 Activation Contribute to Nefazodone-Induced Toxicity in Hepatic Cells. Toxicological Sciences, 2016, 154, 368-380.	1.4	22
41	Editorial: Promising approaches to identify DILI drugs. Chemico-Biological Interactions, 2016, 255, 1-2.	1.7	2
42	InÂvitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries. Chemico-Biological Interactions, 2016, 255, 12-22.	1.7	22
43	Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles. Chemico-Biological Interactions, 2016, 255, 3-11.	1.7	37
44	A Novel Plated Hepatocyte Relay Assay (PHRA) for In Vitro Evaluation of Hepatic Metabolic Clearance of Slowly Metabolized Compounds. Drug Metabolism Letters, 2016, 10, 3-15.	0.5	9
45	Evaluation of Adverse Drug Properties with Cryopreserved Human Hepatocytes and the Integrated Discrete Multiple Organ Co-culture (IdMOC <sup>TM</sup> ) System. Toxicological Research, 2015, 31, 137-149.	1.1	16
46	InÂsitu allicin generation using targeted alliinase delivery for inhibition of MIA PaCa-2 cells via epigenetic changes, oxidative stress and cyclin-dependent kinase inhibitor (CDKI) expression. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 1388-1409.	2.2	37
47	Cryopreservation of Hepatocytes. Methods in Molecular Biology, 2015, 1250, 13-26.	0.4	7
48	Application of a Higher Throughput Approach to Derive Apparent Michaelis-Menten Constants of Isoform-Selective P450-Mediated Biotransformation Reactions in Human Hepatocytes. Drug Metabolism Letters, 2014, 8, 2-11.	0.5	6
49	Evaluation of Human Hepatocytes Under Prolonged Culture in a Novel Medium for the Maintenance of Hepatic Differentiation: Results with the Model Pro-inflammatory Cytokine Interleukin 6. Drug Metabolism Letters, 2014, 8, 12-18.	0.5	12
50	Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma. Clinical Chemistry and Laboratory Medicine, 2014, 52, 899-909.	1.4	43
51	Biomarkers and human hepatocytes. Biomarkers in Medicine, 2014, 8, 173-183.	0.6	8
52	Thymic stromal lymphopoietin and interleukin-4 mediate the pathogenesis of halothane-induced liver injury in mice. Hepatology, 2014, 60, 1741-1752.	3.6	17
53	High Content Analysis of an In Vitro Model for Metabolic Toxicity: Results with the Model Toxicants 4-Aminophenol and Cyclophosphamide. Journal of Biomolecular Screening, 2014, 19, 1402-1408.	2.6	10
54	In Vitro Human Hepatocyte-Based Experimental Systems for the Evaluation of Human Drug Metabolism, Drug-Drug Interactions, and Drug Toxicity in Drug Development. Current Topics in Medicinal Chemistry, 2014, 14, 1325-1338.	1.0	15

#	Article	IF	CITATIONS
55	Culture Duration-, Donor-, and Medium-Dependent Changes in OATP1B3- Mediated Telmisartan Uptake in Human Hepatocytes. Drug Metabolism Letters, 2014, 7, 117-125.	0.5	7
56	Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles. Chemico-Biological Interactions, 2013, 205, A1-A5.	1.7	45
57	Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles. Toxicon, 2013, 76, A1-A2.	0.8	5
58	Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles. Toxicology in Vitro, 2013, 27, 2110-2114.	1.1	18
59	Editorial. Food and Chemical Toxicology, 2013, 62, A1-A4.	1.8	6
60	Editorial. Regulatory Toxicology and Pharmacology, 2013, 67, 317-320.	1.3	9
61	Open letter to the European commission: scientifically unfounded precaution drives European commission's recommendations on EDC regulation, while defying common sense, well-established science, and risk assessment principles. Archives of Toxicology, 2013, 87, 1739-1741.	1.9	24
62	Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles. ALTEX: Alternatives To Animal Experimentation, 2013, 30, 381-385.	0.9	9
63	Effects of Culture Duration on Gene Expression of P450 Isoforms, Uptake and Efflux Transporters in Primary Hepatocytes Cultured in the Absence and Presence of Interleukin- 6: Implications for Experimental Design for the Evaluation of Downregulatory Effects of Biotherapeutics. Current Drug Metabolism. 2012. 13. 938-946.	0.7	21
64	Editorial: [Hot Topics: Metabolism and Drug-Drug Interaction Potential of Biotherapeutics]. Current Drug Metabolism, 2012, 13, 881-881.	0.7	0
65	Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: Results with model toxicants aflatoxin B1, cyclophosphamide and tamoxifen. Chemico-Biological Interactions, 2012, 199, 1-8.	1.7	38
66	Higher Throughput Human Hepatocyte Assays for the Evaluation of Time-Dependent Inhibition of CYP3A4. Drug Metabolism Letters, 2011, 5, 183-191.	0.5	21
67	Luciferin IPA–Based Higher Throughput Human Hepatocyte Screening Assays for CYP3A4 Inhibition and Induction. Journal of Biomolecular Screening, 2011, 16, 903-909.	2.6	28
68	Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. Journal of Pharmacy and Pharmacology, 2010, 55, 1229-1239.	1.2	22
69	Cytotoxicity of eight cigarette smoke condensates in three test systems: Comparisons between assays and condensates. Regulatory Toxicology and Pharmacology, 2010, 58, 428-436.	1.3	28
70	Simultaneous Inhibition of MEK and CDK4 Leads to Potent Apoptosis in Human Melanoma Cells. Cancer Investigation, 2010, 28, 350-356.	0.6	21
71	Simultaneous Inhibition of MEK and CDK4 Leads to Potent Apoptosis in Human Melanoma Cells. Cancer Investigation, 2010, 28, 350-356.	0.6	24
72	Evaluation of Drug Metabolism, Drug–Drug Interactions, and In Vitro Hepatotoxicity with Cryopreserved Human Hepatocytes. Methods in Molecular Biology, 2010, 640, 281-294.	0.4	25

#	Article	IF	CITATIONS
73	Low Prevalence of Non-Subtype B HIV-1 Strains in the Texas Prisoner Population. Journal of Molecular Genetics, 2010, 2, 41-44.	0.2	3
74	The Use of the Integrated Discrete Multiple Organ Co-culture (IdMOC®) System for the Evaluation of Multiple Organ Toxicity. ATLA Alternatives To Laboratory Animals, 2009, 37, 377-385.	0.7	26
75	Evaluation of Luciferin-Isopropyl Acetal as a CYP3A4 Substrate for Human Hepatocytes: Effects of Organic Solvents, Cytochrome P450 (P450) Inhibitors, and P450 Inducers. Drug Metabolism and Disposition, 2009, 37, 1598-1603.	1.7	32
76	Metabolism Comparative Cytotoxicity Assay (MCCA) and Cytotoxic Metabolic Pathway Identification Assay (CMPIA) with cryopreserved human hepatocytes for the evaluation of metabolism-based cytotoxicity in vitro: Proof-of-concept study with aflatoxin B1. Chemico-Biological Interactions, 2009, 179, 4-8.	1.7	31
77	Overview: Evaluation of metabolism-based drug toxicity in drug development. Chemico-Biological Interactions, 2009, 179, 1-3.	1.7	18
78	Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis. Biochemical and Biophysical Research Communications, 2008, 370, 509-513.	1.0	32
79	HIV-1 Genotypic Resistance Testing on Low Viral Load Specimens Using the Abbott ViroSeq HIV-1 Genotyping System. Laboratory Medicine, 2008, 39, 671-673.	0.8	6
80	Human hepatocytes as an effective alternative experimental system for the evaluation of human drug properties: General concepts and assay procedures. ALTEX: Alternatives To Animal Experimentation, 2008, 25, 33-42.	0.9	31
81	In vitro evaluation of human xenobiotic toxicity: Scientific concepts and the novel integrated discrete multiple cell co-culture (IdMOC) technology. ALTEX: Alternatives To Animal Experimentation, 2008, 25, 43-49.	0.9	34
82	Human-Based In Vitro Experimental Systems for the Evaluation of Human Drug Safety. Current Drug Safety, 2007, 2, 193-199.	0.3	17
83	In Vitro Evaluation of Metabolic Drug-Drug Interactions: Scientific Concepts and Practical Considerations. , 2007, , 853-877.		0
84	In Vitro Evaluation of Metabolic Drugâ€Drug Interactions: A Descriptive and Critical Commentary. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al ], 2007, 33, Unit 4.25.	1.1	1
85	Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies. Drug Metabolism Reviews, 2007, 39, 159-234.	1.5	673
86	Human hepatocytes: Isolation, cryopreservation and applications in drug development. Chemico-Biological Interactions, 2007, 168, 16-29.	1.7	179
87	Drug–Drug Interaction –ÂEnzyme Induction. , 2006, , 543-550.		0
88	Preclinical in vitro screening assays for drug-like properties. Drug Discovery Today: Technologies, 2005, 2, 179-185.	4.0	58
89	In Vitro Approaches to Evaluate ADMET Drug Properties. Current Topics in Medicinal Chemistry, 2004, 4, 701-706.	1.0	57
90	Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 549, 101-113.	0.4	97

#	Article	IF	CITATIONS
91	In vitro experimental models for the blood–brain barrier. Drug Discovery Today, 2004, 9, 204-205.	3.2	1
92	An integrated, multidisciplinary approach for drug safety assessment. Drug Discovery Today, 2004, 9, 687-693.	3.2	27
93	Effects of Kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine, 2004, 11, 285-294.	2.3	51
94	An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chemico-Biological Interactions, 2004, 150, 137-147.	1.7	37
95	Accurate prediction of human drug toxicity: a major challenge in drug development. Chemico-Biological Interactions, 2004, 150, 3-7.	1.7	72
96	A comprehensive approach for drug safety assessment. Chemico-Biological Interactions, 2004, 150, 27-33.	1.7	21
97	A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma breast cancer cells. Chemico-Biological Interactions 2004, 150, 129-136	1.7	101
98	Advancing technologies for accelerated drug development. Drug Discovery Today, 2003, 8, 200-202.	3.2	2
99	MAINTENANCE OF LIVER FUNCTIONS IN RAT HEPATOCYTES CULTURED AS SPHEROIDS IN A ROTATING WALL VESSEL. In Vitro Cellular and Developmental Biology - Animal, 2003, 39, 13.	0.7	40
100	Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 610-616.	1.3	324
101	Function of Uptake Transporters for Taurocholate and Estradiol 17β-D-Glucuronide in Cryopreserved Human Hepatocytes. Drug Metabolism and Pharmacokinetics, 2003, 18, 33-41.	1.1	110
102	A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis―for the manifestation of idiosyncratic drug toxicity. Chemico-Biological Interactions, 2002, 142, 7-23.	1.7	160
103	Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. Chemico-Biological Interactions, 2002, 142, 57-71.	1.7	36
104	Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes. Chemico-Biological Interactions, 2002, 142, 73-82.	1.7	30
105	Identification of glutathione conjugates of troglitazone in human hepatocytes. Chemico-Biological Interactions, 2002, 142, 83-97.	1.7	56
106	Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. Chemico-Biological Interactions, 2002, 142, 119-134.	1.7	43
107	A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4′-hydroxylation, chloroxazone 6-hydroxylation and testosterone 6β-hydroxylation. Chemico-Biological Interactions, 2001, 134, 243-249	1.7	58
108	Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague–Dawley rat, minipig, and beagle dog. Chemico-Biological Interactions, 2001, 134, 271-281.	1.7	185

#	Article	IF	CITATIONS
109	Screening for human ADME/Tox drug properties in drug discovery. Drug Discovery Today, 2001, 6, 357-366.	3.2	471
110	In Vitro Human Tissue Models in Risk Assessment: Report of a Consensus-Building Workshop. Toxicological Sciences, 2001, 59, 17-36.	1.4	87
111	Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metabolism and Disposition, 2001, 29, 141-4.	1.7	139
112	2,3,7,8 Tetrachlorodibenzo-p-dioxin induction of cytochrome P4501A in cultured rat and human hepatocytes. Chemico-Biological Interactions, 2000, 124, 173-189.	1.7	72
113	Mechanism-based Preclinical Approaches for the Evaluation of Drug-Drug Interactions Drug Metabolism and Pharmacokinetics, 2000, 15, 228-234.	0.0	0
114	Human hepatocytes as an experimental system for the evaluation of xenobiotics. , 2000, , 391-410.		5
115	Effects of cytochrome P450 inducers on 17α-ethinyloestradiol (EE2 ) conjugation by primary human hepatocytes. British Journal of Clinical Pharmacology, 1999, 48, 733-742.	1.1	64
116	Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. Chemico-Biological Interactions, 1999, 121, 117-123.	1.7	137
117	Overview: hepatocytes and cryopreservation—a personal historical perspective. Chemico-Biological Interactions, 1999, 121, 1-5.	1.7	28
118	Cryopreserved human hepatocytes: characterization of drug-metabolizing activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug–drug interaction potential. Chemico-Biological Interactions, 1999, 121, 17-35.	1.7	280
119	An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chemico-Biological Interactions, 1998, 114, 1-13.	1.7	41
120	The Scientific Basis of Drug-Drug Interactions: Mechanism and Preclinical Evaluation. Drug Information Journal, 1998, 32, 657-664.	0.5	13
121	Primary Hepatocyte Cultures as an in Vitro Experimental Model for the Evaluation of Pharmacokinetic Drug–Drug Interactions. Advances in Pharmacology, 1997, 43, 103-130.	1.2	42
122	Overview: Pharmacokinetic Drug-Drug Interactions. Advances in Pharmacology, 1997, 43, 1-6.	1.2	11
123	Primary hepatocyte culture as an experimental model for the evaluation of interactions between xenobiotics and drug-metabolizing enzymes. Chemico-Biological Interactions, 1997, 107, 1-3.	1.7	5
124	Preclinical evaluation of drug—drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chemico-Biological Interactions, 1997, 107, 5-16.	1.7	128
125	Primary human hepatocytes as a tool for the evaluation of structure—activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chemico-Biological Interactions, 1997, 107, 17-30.	1.7	144
126	Quantitative reverse transcriptase/PCR assay for the measurement of induction in cultured hepatocytes. Chemico-Biological Interactions, 1997, 107, 47-61.	1.7	18

#	Article	IF	CITATIONS
127	Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin. , 1997, 13, 365-374.		46
128	The Effects of Trinitrobenzene Sulfonic Acid (TNB) on Colonocyte Arachidonic Acid Metabolism. Journal of Surgical Research, 1996, 60, 375-378.	0.8	8
129	The effect of prostanoids on hepatic bile flow in dogs with normal liver and bile duct cell hyperplasia. Prostaglandins Leukotrienes and Essential Fatty Acids, 1996, 54, 265-271.	1.0	1
130	Evaluation of drug interactions in intact hepatocytes: Inhibitors of terfenadine metabolism. Toxicology in Vitro, 1996, 10, 655-663.	1.1	18
131	Role of protein kinase a in human hepatocyte DNA synthesis. Digestive Diseases and Sciences, 1996, 41, 1014-1021.	1.1	1
132	Substrates of human hepatic cytochrome P450 3A4. Toxicology, 1995, 104, 1-8.	2.0	335
133	Isolation and culturing of primary human colonocytes. Cytotechnology, 1995, 17, 195-198.	0.7	0
134	Polybrominated biphenyl induction of cytochrome P450 mixed function oxidase activity in primary rat and human hepatocytes. Toxicology, 1995, 99, 147-152.	2.0	32
135	Lysophosphatidylcholine-stimulated protein and glycoprotein production by human gallbladder mucosal cells. Digestive Diseases and Sciences, 1995, 40, 1990-1996.	1.1	6
136	Gallbladder mucosal protein secretion during development of experimental cholecystitis. Digestive Diseases and Sciences, 1995, 40, 1157-1164.	1.1	3
137	Cytotoxicity of Ethylene Oxide/Propylene Oxide Copolymers in Cultured Mammalian Cells. Drug and Chemical Toxicology, 1995, 18, 29-41.	1.2	8
138	Glutamine transport in isolated human hepatocytes and transformed liver cells*1. Hepatology, 1995, 21, 511-520.	3.6	6
139	Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. Journal of Pharmacology and Experimental Therapeutics, 1995, 274, 673-7.	1.3	41
140	Glutamine transport in isolated human hepatocytes and transformed liver cells. Hepatology, 1995, 21, 511-20.	3.6	50
141	The effect of Clostridium difficile toxin on colonocyte prostanoid activity. Prostaglandins, 1994, 48, 367-375.	1.2	11
142	Studies on the etiology of acute acalculous cholecystitis: The effect of lipopolysaccharide on human gallbladder mucosal cells. Prostaglandins, 1994, 47, 319-330.	1.2	23
143	Comparative metabolism of SC-42867 and SC-51089, two PGE2antagonists, in rat and human hepatocyte cultures. Xenobiotica, 1994, 24, 25-36.	0.5	20
144	Culturing of primary hepatocytes as entrapped aggregates in a packed bed bioreactor: A potential bioartificial liver. In Vitro Cellular & Developmental Biology, 1993, 29, 249-254.	1.0	64

#	Article	IF	CITATIONS
145	Metabolism in vitro of radioiodinated N-isopropyl-p-iodoamphetamine by isolated hepatocytes. Nuclear Medicine and Biology, 1993, 20, 49-56.	0.3	10
146	METABOLISM OF ENDOGENOUS AND XENOBIOTIC SUBSTANCES BY PULMONARY VASCULAR ENDOTHELIAL CELLS. , 1993, , 107-122.		0
147	Toxicity of Calcium Sodium Metaphosphate Fiber. Toxicological Sciences, 1992, 19, 69-78.	1.4	1
148	Toxicity of calcium sodium metaphosphate fiber *11. In vitro and in vivo degradation and clearance studies. Fundamental and Applied Toxicology, 1992, 19, 69-78.	1.9	2
149	Gene transfer in primary cultures of human hepatocytes. In Vitro Cellular and Developmental Biology - Animal, 1992, 28, 373-375.	0.7	21
150	A simplified method for the culturing of primary adult rat and human hepatocytes as multicellular spheroids. In Vitro Cellular & Developmental Biology, 1992, 28, 673-677.	1.0	76
151	Isolation and culturing of hepatocytes from human livers. Cytotechnology, 1992, 14, 139-145.	0.3	95
152	Comparison of rat liver parenchymal and nonparenchymal cells in the activation of promutagens. Environmental and Molecular Mutagenesis, 1992, 20, 134-139.	0.9	12
153	An evaluation of the roles of mammalian cell mutation assays in the testing of chemical genotoxicity. Regulatory Toxicology and Pharmacology, 1991, 14, 24-40.	1.3	23
154	Epidermal growth factor, DNA synthesis and human hepatocytes. In Vitro Cellular & Developmental Biology, 1991, 27, 831-833.	1.0	9
155	Sulfation and glucuronidation of acetaminophen by cultured hepatocytes reproducing in vivo sex-differences in conjugation on matrigel and type 1 collagen. In Vitro Cellular & Developmental Biology, 1991, 27, 953-960.	1.0	18
156	Overview: Industrial perspectives on existing in vivo gene mutation assays. Environmental and Molecular Mutagenesis, 1991, 18, 292-294.	0.9	0
157	Spontaneous frequency of 6-thioguanine resistant mutants in CHO-AS52 cells after prolonged culturing in the absence of selective agents. Environmental and Molecular Mutagenesis, 1990, 15, 214-217.	0.9	4
158	Sulfation and glucuronidation of acetaminophen by cultured hepatocytes replicating in vivo metabolism. ASAIO Transactions, 1990, 36, M607-10.	0.2	8
159	Optimization of Cryopreservation Procedures for Rat and Human Hepatocytes. Xenobiotica, 1989, 19, 489-498.	0.5	154
160	Promutagen activation by freshly isolated and cryopreserved rat hepatocytes. Environmental Mutagenesis, 1988, 12, 335-341.	1.4	14
161	A review and analysis of the Chinese hamster ovary/hypoxanthine guanine phosphoribosyl transferase assay to determine the mutagenicity of chemical agents. A report of phase III of the U.S. environmental protection agency Gene-Tox program. Mutation Research - Reviews in Genetic Toxicology, 1988, 196, 17-36.	3.0	37
162	An Evaluation of the Genotoxic Potential of Glyphosate. Toxicological Sciences, 1988, 10, 537-546.	1.4	3

#	Article	IF	CITATIONS
163	An evaluation of the genotoxic potential of glyphosate*1. Fundamental and Applied Toxicology, 1988, 10, 537-546.	1.9	52
164	In vitro evaluation of the cytotoxic potential of a novel man-made fiber, calcium sodium metaphosphate fiber (Phosphate Fiber). Fundamental and Applied Toxicology, 1988, 11, 21-28.	1.9	10
165	A guide for the performance of the Chinese hamster ovary cell/hypoxanthine-guanine phosphoribosyl transferase gene mutation assay. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1987, 189, 135-141.	1.2	60
166	Mutagenicity of used crankcase oils from diesel and spark ignition automobiles. Environmental Research, 1986, 40, 155-163.	3.7	15
167	An In vitro lung epithelial cell system for evaluating the potential toxicity of inhalable materials. Food and Chemical Toxicology, 1986, 24, 527-534.	1.8	12
168	A testing strategy to evaluate the mutagenic activity of industrial chemicals in cultured mammalian cells. Regulatory Toxicology and Pharmacology, 1985, 5, 207-211.	1.3	4
169	The use of sister-chromatid exchange in Chinese hamster primary lung cell cultures to measure genotoxicity. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1984, 130, 333-342.	0.4	9
170	Use of aroclor 1254-induced rat liver homogenate in the assaying of promutagens in chinese hamster ovary cells. Environmental Mutagenesis, 1984, 6, 539-544.	1.4	24
171	A comparison of genotoxicity of automotive exhaust particles from laboratory and environmental sources. Environmental Mutagenesis, 1984, 6, 651-668.	1.4	23
172	Evaluation of the genotoxicity of process stream extracts from a coal gasification system. Environmental Mutagenesis, 1984, 6, 825-834.	1.4	8
173	Chemical and biological properties of diesel exhaust particles collected during selected segments of a simulated driving cycle*1. Fundamental and Applied Toxicology, 1984, 4, 370-377.	1.9	14
174	The Induction of Sister Chromatid Exchanges by Environmental Pollutants: Relationship of SCE to Other Measures of Genetic Damage. , 1984, 29 Pt A, 385-396.		2
175	A modified agar assay for the quantitation of mutation at the hypoxanthine guanine phosphoribosyl transferase gene locus in Chinese hamster ovary cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1983, 111, 365-370.	0.4	15
176	Mutagenicity of mono-, di- and tri-nitropyrenes in Chinese hamster ovary cells. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1983, 119, 387-392.	1.2	69
177	Isolation and culturing of rat pulmonary alveolar macrophages. Cytotechnology, 1983, 8, 91-94.	0.3	7
178	Comparative mutagenicity of a coal combustion fly ash extract in salmonella typhimurium and chinese hamster ovary cells. Environmental Mutagenesis, 1983, 5, 263-272.	1.4	21
179	Rat nasal tissue activation of benzo(a)pyrene and 2-aminoanthracene to mutagens in salmonella typhimurium. Environmental Mutagenesis, 1983, 5, 311-318.	1.4	16
180	Evaluation of an exposure system using cells grown on collagen gels for detecting highly volatile mutagens in the CHO/HGPRT mutation assay. Environmental Mutagenesis, 1983, 5, 795-801.	1.4	30

#	Article	IF	CITATIONS
181	Characterization of a lung epithelial cell strain with potential applications in toxicological studies. Toxicology, 1983, 27, 257-272.	2.0	41
182	Triple-quadrupole mass spectrometry studies of nitroaromatic emissions from different diesel engines. Environmental Science & Technology, 1983, 17, 443-449.	4.6	50
183	Metabolism and macromolecular covalent binding of benzo[a]pyrene in cultured fischer-344 rat lung type II epithelial cells. Biochemical Pharmacology, 1983, 32, 3771-3776.	2.0	14
184	Cytotoxicity and mutagenicity of vaporâ€phase pollutants in rat lung epithelial cells and Chinese hamster ovary cells grown on collagen gels. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1983, 12, 27-38.	1.1	12
185	Mutagenicity Testing of Complex Environmental Mixtures with Chinese Hamster Ovary Cells. , 1983, , 183-196.		9
186	Acute and genetic toxicity of 1â€nitropyrene and its fate after single oral doses to rats. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1982, 10, 373-384.	1.1	29
187	Diesel-exhaust-particle extract enhancement of chemical-induced mutagenesis in cultured Chinese hamster ovary cells: Possible interaction of diesel exhaust with environmental carcinogens. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1982, 103, 349-355.	1.2	21
188	In vitro cytotoxicity and genotoxicity of dibutyltin dichloride and dibutylgermanium dichloride. Toxicology and Applied Pharmacology, 1982, 64, 482-485.	1.3	43
189	Quantification of mutations at the Na+-K+-ATPase and hypoxanthine — guanine phosphoribosyl transferase (HGPRT) gene loci in Chinese hamster ovary cells. Cytotechnology, 1982, 7, 27-32.	0.3	5
190	Cytotoxicity of diesel exhaust particle extract — A comparison among five diesel passenger cars of different manufacturers. Toxicology, 1982, 24, 1-8.	2.0	9
191	Increased cytotoxicity and mutagenicity of diesel fuel after reaction with NO2. Environmental Mutagenesis, 1981, 3, 211-220.	1.4	25
192	Simplification of the CHO/HGPRT mutation assay through the growth of Chinese hamster ovary cells as unattached cultures. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1981, 85, 165-175.	0.4	31
193	Antagonistic effects of animal sera, lung and liver cytosols, and sulfhydryl compounds on the cytotoxicity of diesel exhaust particle extracts. Toxicology and Applied Pharmacology, 1981, 57, 55-62.	1.3	33
194	Growth of mammalian cells as unattached cultures on nontissue culture plates. Cytotechnology, 1980, 6, 71-73.	0.3	4
195	Quantitative Analyses of Radiation- and Chemical-Induced Lethality and Mutagenesis in Chinese Hamster Ovary Cells. Radiation Research, 1978, 76, 471.	0.7	37
196	Characterization of two adenosine 3′:5′-phosphate-dependent protein kinase species from Chinese hamster ovary cells. Biochimica Et Biophysica Acta - Biomembranes, 1978, 527, 403-413.	1.4	3
197	Growth fraction as the major determinant of multicellular tumor spheroid growth rates. Cancer Research, 1978, 38, 1528-32.	0.4	44
198	Studies on adenosine 3′,5′-phosphate-binding and adenosine 3′,5′-phosphate-dependent protein kina activities associated with subcellular fractions of Chinese hamster ovary cells. Biochimica Et Biophysica Acta - General Subjects, 1977, 500, 140-151.	se 1.1	7

#	Article	IF	CITATIONS
199	Action of cyclic nucleotide analgoues in Chinese hamster ovary cells. Biochimica Et Biophysica Acta - General Subjects, 1977, 497, 35-45.	1.1	14
200	Correlation between changes in intracellular level of cyclic AMP, activation of cyclic AMP-dependent protein kinase, and the morphology of Chinese hamster ovary cells in culture. Archives of Biochemistry and Biophysics, 1977, 182, 181-187.	1.4	30
201	A fluence response study of lethality and mutagenicity of white black, and blue fluorescent light, sunlamp, and sunlight irradiation in Chinese hamster ovary cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1977, 45, 333-342.	0.4	56
202	A simplified method for production and growth of multicellular tumor spheroids. Cancer Research, 1977, 37, 3639-43.	0.4	396
203	In vivo activation of cyclic adenosine 3′:5′-phosphate-dependent protein kinase in Chinese hamster ovary cells treated with N6, O2′-dibutyryl cyclic adenosine 3′:5′-phosphate. Biochemical and Biophysical Research Communications, 1975, 64, 507-513.	1.0	14
204	In Vitro Evaluation of Metabolic Drug–Drug Interactions: Concepts and Practice. , 0, , 1-29.		1
205	Transporters and Drug Interactions. , 0, , 131-157.		0
206	Human-Basedin vitro Experimental Systems for the Evaluation of Human Drug Safety. , 0, , 89-104.		0
207	In vitro evaluation of metabolic drug–drug interactions. , 0, , 76-101.		0
208	Evaluation of Inhibitors of Drug Metabolism in Human Hepatocytes. , 0, , 423-441.		3